文献速递前列腺癌

寡复发转移性前列腺癌的全身与肿瘤定向治疗(SATURN):2期临床试验主要终点结果

Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
PubMed 文献 · Eur Urol · 2024-03-16

这项单臂2期试验纳入28例根治性前列腺切除术后PSMA PET/CT发现1–5个非内脏、盆腔外转移的前列腺癌患者,接受6个月雄激素 annihilation 治疗(亮丙瑞林、阿比特龙联合泼尼松、阿帕他胺)及转移灶立体定向体部放疗。主要终点为睾酮恢复后6个月PSA<0.05 ng/ml的比例,结果为13/26(50%,95%CI 32–67%)。

要点

  • 睾酮恢复后6个月,13/26例(50%,95%CI 32–67%)维持PSA<0.05 ng/ml。
  • 2级和3级雄激素 annihilation 治疗毒性发生率均为21%。
  • 26例(93%)完成SBRT联合6个月激素治疗,其中6例停用至少一种ARPI。

核心结论

  • 在高效全身治疗基础上加用转移灶定向SBRT可在睾酮恢复后维持低PSA,但需进一步研究明确最佳全身治疗方案。

研究设计与样本

  • 单臂2期临床试验,纳入28例根治性前列腺切除术后PSMA PET/CT发现1–5个非内脏、盆腔外转移的 men,2021年3月至2022年6月入组。
  • 患者接受6个月雄激素 annihilation 治疗(亮丙瑞林、阿比特龙联合泼尼松、阿帕他胺)及转移灶定向SBRT。
  • 主要终点为睾酮恢复(≥150 ng/dl)后6个月PSA<0.05 ng/ml的患者百分比,研究把握度设计为检测从1%到12%的改善。

主要发现

  • 中位随访20个月(四分位距16–22)。
  • 26例(93%)完成SBRT联合6个月激素治疗,其中6例停用至少一种ARPI;2例提前退出。
  • 睾酮恢复后6个月,13/26例(50%,95%CI 32–67%)维持PSA<0.05 ng/ml。
  • 2级和3级雄激素 annihilation 治疗毒性发生率分别为21%和21%。

局限性

  • 需进一步研究明确最佳全身治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nearly all men with metastatic hormone-sensitive prostate cancer treated with intermittent androgen deprivation therapy (ADT) experience recurrence within 6 mo of testosterone recovery. We conducted a single-arm phase 2 trial to evaluate whether addition of dual androgen receptor pathway inhibitors (ARPIs) and metastasis-directed stereotactic body radiotherapy (SBRT) to intermittent ADT improves recurrence rates for men with between one and five nonvisceral, extrapelvic metastases on prostate-specific membrane antigen positron emission tomography/computed tomography after prior radical prostatectomy. Patients received 6 mo of androgen annihilation therapy (AAT; leuprolide, abiraterone acetate plus prednisone, and apalutamide) and metastasis-directed SBRT. The primary endpoint was the percentage of patients with prostate-specific antigen (PSA) <0.05 ng/ml 6 mo after testosterone recovery (≥150 ng/dl), with the study powered to detect an improvement from 1% to 12%. We enrolled 28 men between March 2021 and June 2022. Median follow-up was 20 mo (interquartile range 16-22). Twenty-six patients (93%) completed SBRT with 6 mo of hormone therapy, of whom six discontinued at least one ARPI; two patients withdrew prematurely. At 6 mo after testosterone recovery, PSA was maintained at <0.05 ng/ml in 13/26 patients (50%, 95% confidence interval 32-67%). Rates of grade 2 and 3 AAT toxicity were 21% and 21%. The results confirm that addition of metastasis-directed SBRT to highly potent systemic therapy can maintain low PSA after testosterone recovery, although further studies are needed to clarify the optimal systemic therapy regimen. PATIENT SUMMARY: We tested a combination of intensified hormone therapy (called androgen annihilation therapy) and radiotherapy targeted at metastases in men with recurrence of metastatic prostate cancer. We found that half of patients were recurrence-free 6 months after their testosterone level recovered, and that less than a quarter of patients experienced a severe drug-related side effect. Overall, this appears to be an effective therapy with acceptable side effects. This trial is registered on ClinicalTrials.gov as NCT03902951.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Nikitas J, Rettig M, Shen J, et al. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. Eur Urol. 2024. PMID: 38494380. doi:10.1016/j.eururo.2024.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。